{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:17:46Z","timestamp":1789154266905,"version":"build-2803163510"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s40266-025-01233-1","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T05:41:59Z","timestamp":1753767719000},"page":"907-920","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Sacubitril\/Valsartan Reduces the Risk of All-Cause Dementia in Patients with Heart Failure: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-6387-623X","authenticated-orcid":false,"given":"Mohamed Mohsen","family":"Helal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nereen A.","family":"Almosilhy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada G.","family":"Hamam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Ahmed Adel","family":"Abdelbaset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Nagy","family":"Shelbaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halima Abdirashid Y.","family":"Musse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aishwarya","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,29]]},"reference":[{"key":"1233_CR1","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1046\/j.0306-5251.2001.1420.x","volume":"52","author":"IB Wilkinson","year":"2001","unstructured":"Wilkinson IB, McEniery CM, Bongaerts KH, MacCallum H, Webb DJ, Cockcroft JR. Adrenomedullin (ADM) in the human forearm vascular bed: effect of neutral endopeptidase inhibition and comparison with proadrenomedullin NH2-terminal 20 peptide (PAMP). Br J Clin Pharmacol. 2001;52:159\u201364.","journal-title":"Br J Clin Pharmacol"},{"key":"1233_CR2","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1042\/cs0910283","volume":"91","author":"MT Rademaker","year":"1996","unstructured":"Rademaker MT, Charles CJ, Espiner EA, Nicholls MG, Richards AM, Kosoglou T. Neutral endopeptidase inhibition: augmented atrial and brain natriuretic peptide, haemodynamic and natriuretic responses in ovine heart failure. Clin Sci. 1996;91:283\u201391.","journal-title":"Clin Sci"},{"key":"1233_CR3","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1161\/01.HYP.0000146483.78994.56","volume":"44","author":"NLM Cruden","year":"2004","unstructured":"Cruden NLM, Fox KAA, Ludlam CA, Johnston NR, Newby DE. Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition. Hypertension. 2004;44:913\u20138.","journal-title":"Hypertension"},{"key":"1233_CR4","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s00395-004-0460-0","volume":"99","author":"M Kuhn","year":"2004","unstructured":"Kuhn M. Molecular physiology of natriuretic peptide signalling. Basic Res Cardiol. 2004;99:76\u201382.","journal-title":"Basic Res Cardiol"},{"key":"1233_CR5","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000092457","volume":"103","author":"C Maric","year":"2006","unstructured":"Maric C, Zheng W, Walther T. Interactions between angiotensin ll and atrial natriuretic peptide in renomedullary interstitial cells: the role of neutral endopeptidase. Nephron Physiol. 2006;103:149\u201356.","journal-title":"Nephron Physiol"},{"key":"1233_CR6","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1161\/01.HYP.0000054215.71691.16","volume":"41","author":"DJ Campbell","year":"2003","unstructured":"Campbell DJ. Vasopeptidase inhibition: a double-edged sword? Hypertension. 2003;41:383\u20139.","journal-title":"Hypertension"},{"key":"1233_CR7","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1136\/heartjnl-2017-311295","volume":"103","author":"JSS Singh","year":"2017","unstructured":"Singh JSS, Burrell LM, Cherif M, Squire IB, Clark AL, Lang CC. Sacubitril\/valsartan: beyond natriuretic peptides. Heart. 2017;103:1569\u201377.","journal-title":"Heart"},{"key":"1233_CR8","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJV McMurray","year":"2014","unstructured":"McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993\u20131004.","journal-title":"N Engl J Med"},{"key":"1233_CR9","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1093\/eurjhf\/hft052","volume":"15","author":"JJV McMurray","year":"2013","unstructured":"McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau J, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Committees and Investigators. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail. 2013;15:1062\u201373.","journal-title":"Eur J Heart Fail"},{"key":"1233_CR10","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/nrcardio.2016.200","volume":"14","author":"DJ Campbell","year":"2017","unstructured":"Campbell DJ. Long-term neprilysin inhibition\u2014implications for ARNIs. Nat Rev Cardiol. 2017;14:171\u201386.","journal-title":"Nat Rev Cardiol"},{"key":"1233_CR11","unstructured":"Unger EF. Approval letter\u2014US Food and Drug Administration. FDA http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2015\/207620Orig1s000ltr.pdf. 2015."},{"key":"1233_CR12","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jacc.2016.05.011","volume":"68","author":"CW Yancy","year":"2016","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, Drazner MH, Filippatos G, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C. 2016 ACC\/AHA\/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the american college of cardiology\/american heart association task force on clinical practice guidelines and the heart failure society of america. J Am Coll Cardiol. 2016;68:1476\u201388.","journal-title":"J Am Coll Cardiol"},{"key":"1233_CR13","unstructured":"Novartis Entresto\u00ae granted expanded indication in chronic heart failure by FDA. Novartis https:\/\/www.novartis.com\/news\/media-releases\/novartis-entresto-granted-expanded-indication-chronic-heart-failure-fda"},{"key":"1233_CR14","unstructured":"Centers for Medicare & Medicaid Services Data. Available from: https:\/\/data.cms.gov\/summary-statistics-on-use-and-payments\/medicare-medicaid-spending-by-drug\/medicare-part-d-spending-by-drug"},{"key":"1233_CR15","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/archinte.166.9.1003","volume":"166","author":"C Qiu","year":"2006","unstructured":"Qiu C, Winblad B, Marengoni A, Klarin I, Fastbom J, Fratiglioni L. Heart failure and risk of dementia and Alzheimer disease: a population-based cohort study. Arch Intern Med. 2006;166:1003\u20138.","journal-title":"Arch Intern Med"},{"key":"1233_CR16","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1177\/1533317515618799","volume":"31","author":"AS Chitnis","year":"2016","unstructured":"Chitnis AS, Aparasu RR, Chen H, Kunik ME, Schulz PE, Johnson ML. Use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and risk of dementia in heart failure. Am J Alzheimers Dis Other Demen. 2016;31:395\u2013404.","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"1233_CR17","volume":"28","author":"NH Ali","year":"2024","unstructured":"Ali NH, Al-Kuraishy HM, Al-Gareeb AI, Alnaaim SA, Alexiou A, Papadakis M, Khalifa AA, Saad HM, Batiha GE-S. Neprilysin inhibitors and risk of Alzheimer\u2019s disease: a future perspective. J Cell Mol Med. 2024;28: e17993.","journal-title":"J Cell Mol Med"},{"key":"1233_CR18","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0304-3940(00)01675-X","volume":"297","author":"K Yasojima","year":"2001","unstructured":"Yasojima K, Akiyama H, McGeer EG, McGeer PL. Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of beta-amyloid peptide. Neurosci Lett. 2001;297:97\u2013100.","journal-title":"Neurosci Lett"},{"key":"1233_CR19","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1126\/science.1059946","volume":"292","author":"N Iwata","year":"2001","unstructured":"Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, Gerard C, Hama E, Lee HJ, Saido TC. Metabolic regulation of brain Abeta by neprilysin. Science. 2001;292:1550\u20132.","journal-title":"Science"},{"key":"1233_CR20","first-page":"394632023116146","volume":"37","author":"AS El-Din Hussein","year":"2023","unstructured":"El-Din Hussein AS, Abou-El Nour RKE-D, Khorshid OA, Osman AS. Study of the possible effect of sacubitril\/valsartan combination versus valsartan on the cognitive function in Alzheimer\u2019s disease model in rats. Int J Immunopathol Pharmacol. 2023;37:3946320231161469.","journal-title":"Int J Immunopathol Pharmacol"},{"key":"1233_CR21","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/fcp.12837","volume":"37","author":"SH Hammadi","year":"2023","unstructured":"Hammadi SH, Hassan MA, Allam EA, Elsharkawy AM, Shams SS. Effect of sacubitril\/valsartan on cognitive impairment in colchicine-induced Alzheimer\u2019s model in rats. Fundam Clin Pharmacol. 2023;37:275\u201386.","journal-title":"Fundam Clin Pharmacol"},{"key":"1233_CR22","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1093\/eurheartj\/ehv015","volume":"36","author":"N Vodovar","year":"2015","unstructured":"Vodovar N, Paquet C, Mebazaa A, Launay J-M, Hugon J, Cohen-Solal A. Neprilysin, cardiovascular, and Alzheimer\u2019s diseases: the therapeutic split? Eur Heart J. 2015;36:902\u20135.","journal-title":"Eur Heart J"},{"key":"1233_CR23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.173851","volume":"894","author":"E Poorgolizadeh","year":"2021","unstructured":"Poorgolizadeh E, Homayouni Moghadam F, Dormiani K, Rezaei N, Nasr-Esfahani MH. Do neprilysin inhibitors walk the line? Heart ameliorative but brain threatening! Eur J Pharmacol. 2021;894: 173851.","journal-title":"Eur J Pharmacol"},{"key":"1233_CR24","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ejhf.687","volume":"19","author":"JA Cannon","year":"2017","unstructured":"Cannon JA, Shen L, Jhund PS, Kristensen SL, K\u00f8ber L, Chen F, Gong J, Lefkowitz MP, Rouleau JL, Shi VC, Swedberg K, Zile MR, Solomon SD, Packer M, McMurray JJV, PARADIGM-HF Investigators and Committees. Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction. Eur J Heart Fail. 2017;19:129\u201337.","journal-title":"Eur J Heart Fail"},{"key":"1233_CR25","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1161\/CIRCULATIONAHA.124.068774","volume":"150","author":"P Dewan","year":"2024","unstructured":"Dewan P, Shen L, Pedro Ferreira J, Jhund PS, Anand IS, Chandra A, Chiang L-M, Claggett B, Desai AS, Gong J, Lam CSP, Lefkowitz MP, Maggioni AP, Martinez F, Packer M, Redfield MM, Rouleau JL, van Veldhuisen DJ, Zannad F, Zile MR, McMurray JJV. Effect of sacubitril\/valsartan on cognitive function in patients with heart failure with preserved ejection fraction: a prespecified analysis of PARAGON-HF. Circulation. 2024;150:272\u201382.","journal-title":"Circulation"},{"key":"1233_CR26","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2023.100372","volume":"2","author":"PK Grewal","year":"2023","unstructured":"Grewal PK, Abboud A, Myserlis EP, Goldschmidt ME, Butler J, Skopicki HA, Kalogeropoulos AP. Sacubitril\/valsartan and cognitive outcomes in heart failure with reduced ejection fraction. JACC Adv. 2023;2: 100372.","journal-title":"JACC Adv"},{"key":"1233_CR27","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/FJC.0000000000001451","volume":"82","author":"W-S Hu","year":"2023","unstructured":"Hu W-S, Lin C-L. Angiotensin receptor-neprilysin inhibitor versus renin-angiotensin system inhibitor for dementia risk in patients with heart failure. J Cardiovasc Pharmacol. 2023;82:229\u201334.","journal-title":"J Cardiovasc Pharmacol"},{"key":"1233_CR28","doi-asserted-by":"crossref","first-page":"16408","DOI":"10.1038\/s41598-024-67050-5","volume":"14","author":"SK Kim","year":"2024","unstructured":"Kim SK, Kim MG. Subgroup disproportionality analysis of dementia-related adverse events with sacubitril\/valsartan across geographical regions. Sci Rep. 2024;14:16408.","journal-title":"Sci Rep"},{"key":"1233_CR29","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00392-023-02322-0","volume":"113","author":"H-J Lee","year":"2024","unstructured":"Lee H-J, Kim H-K, Kim B-S, Han K-D, Kwak S, Park CS, Rhee T-M, Park J-B, Lee H, Kim Y-J. Sacubitril\/valsartan and the risk of incident dementia in heart failure: a nationwide propensity-matched cohort study. Clin Res Cardiol. 2024;113:875\u201383.","journal-title":"Clin Res Cardiol"},{"key":"1233_CR30","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jad.2020.03.158","volume":"272","author":"F Cacciatore","year":"2020","unstructured":"Cacciatore F, Amarelli C, Maiello C, Pratillo M, Tosini P, Mattucci I, Salerno G, Curcio F, Elia F, Mercurio V, Golino P, Bonaduce D, Abete P. Effect of Sacubitril-Valsartan in reducing depression in patients with advanced heart failure. J Affect Disord. 2020;272:132\u20137.","journal-title":"J Affect Disord"},{"key":"1233_CR31","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s00059-018-4683-5","volume":"44","author":"R De Vecchis","year":"2019","unstructured":"De Vecchis R, Ariano C, Di Biase G, Noutsias M. Cognitive performance of patients with chronic heart failure on sacubitril\/valsartan: a retrospective cohort study. Herz. 2019;44:534\u201340.","journal-title":"Herz"},{"key":"1233_CR32","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1136\/heartjnl-2020-318074","volume":"107","author":"TE Zandstra","year":"2021","unstructured":"Zandstra TE, Nederend M, Jongbloed MRM, Ki\u00e8s P, Vliegen HW, Bouma BJ, Tops LF, Schalij MJ, Egorova AD. Sacubitril\/valsartan in the treatment of systemic right ventricular failure. Heart. 2021;107:1725\u201330.","journal-title":"Heart"},{"key":"1233_CR33","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.cardfail.2018.04.010","volume":"24","author":"A Perlman","year":"2018","unstructured":"Perlman A, Hirsh Raccah B, Matok I, Muszkat M. Cognition- and dementia-related adverse effects with sacubitril-valsartan: analysis of the FDA Adverse Event Report System Database. J Card Fail. 2018;24:533\u20136.","journal-title":"J Card Fail"},{"key":"1233_CR34","volume":"88","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Moher D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Int J Surg. 2021;88: 105906.","journal-title":"Int J Surg"},{"key":"1233_CR35","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5:210.","journal-title":"Syst Rev"},{"key":"1233_CR36","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603\u20135.","journal-title":"Eur J Epidemiol"},{"key":"1233_CR37","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett MS, Eldridge SM, Emberson JR, Hern\u00e1n MA, Hopewell S, Hr\u00f3bjartsson A, Junqueira DR, J\u00fcni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898.","journal-title":"BMJ"},{"key":"1233_CR38","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1001\/archpediatrics.2009.31","volume":"163","author":"P Cummings","year":"2009","unstructured":"Cummings P. The relative merits of risk ratios and odds ratios. Arch Pediatr Adolesc Med. 2009;163:438\u201345.","journal-title":"Arch Pediatr Adolesc Med"},{"key":"1233_CR39","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ & Welch VA (eds.) Cochrane Handbook For Systematic Reviews Of Interventions, Version 6.5 (updated August 2024). Cochrane, 2024. www.training.cochrane.org\/handbook."},{"key":"1233_CR40","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/alz.12101","volume":"16","author":"Y Shang","year":"2020","unstructured":"Shang Y, Fratiglioni L, Marseglia A, Plym A, Welmer A-K, Wang H-X, Wang R, Xu W. Association of diabetes with stroke and post-stroke dementia: a population-based cohort study. Alzheimers Dement. 2020;16:1003\u201312.","journal-title":"Alzheimers Dement"},{"key":"1233_CR41","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/CIRCOUTCOMES.113.000121","volume":"6","author":"AM Hajduk","year":"2013","unstructured":"Hajduk AM, Kiefe CI, Person SD, Gore JG, Saczynski JS. Cognitive change in heart failure: a systematic review. Circ Cardiovasc Qual Outcomes. 2013;6:451\u201360.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"Suppl 1","key":"1233_CR42","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/j.arr.2010.08.006","volume":"9","author":"C-W Hung","year":"2010","unstructured":"Hung C-W, Chen Y-C, Hsieh W-L, Chiou S-H, Kao C-L. Ageing and neurodegenerative diseases. Ageing Res Rev. 2010;9(Suppl 1):S36-46.","journal-title":"Ageing Res Rev"},{"issue":"4","key":"1233_CR43","first-page":"1","volume":"1","author":"S Alsuwaidan","year":"2021","unstructured":"Alsuwaidan S, Algharbi A, Alyami S, Almukhlifi N, Alsalamah S. Prevalence of comorbidity among elderly. Glob J Aging Geriatr Res. 2021;1(4):1\u20134.","journal-title":"Glob J Aging Geriatr Res."},{"key":"1233_CR44","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.631770","volume":"13","author":"JA Santiago","year":"2021","unstructured":"Santiago JA, Potashkin JA. The impact of disease comorbidities in alzheimer\u2019s disease. Front Aging Neurosci. 2021;13: 631770.","journal-title":"Front Aging Neurosci"},{"key":"1233_CR45","unstructured":"McMurray JJ. PERSPECTIVE\u2013Sacubitril\/valsartan and cognitive function in HFmrEF and HFpEF."},{"key":"1233_CR46","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/bcp.12861","volume":"81","author":"TH Langenickel","year":"2016","unstructured":"Langenickel TH, Tsubouchi C, Ayalasomayajula S, Pal P, Valentin M-A, Hinder M, Jhee S, Gevorkyan H, Rajman I. The effect of LCZ696 (sacubitril\/valsartan) on amyloid-\u03b2 concentrations in cerebrospinal fluid in healthy subjects. Br J Clin Pharmacol. 2016;81:878\u201390.","journal-title":"Br J Clin Pharmacol"},{"key":"1233_CR47","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.taap.2017.03.014","volume":"323","author":"HA Schoenfeld","year":"2017","unstructured":"Schoenfeld HA, West T, Verghese PB, Holubasch M, Shenoy N, Kagan D, Buono C, Zhou W, DeCristofaro M, Douville J, Goodrich GG, Mansfield K, Saravanan C, Cumin F, Webb RL, Bateman RJ. The effect of angiotensin receptor neprilysin inhibitor, sacubitril\/valsartan, on central nervous system amyloid-\u03b2 concentrations and clearance in the cynomolgus monkey. Toxicol Appl Pharmacol. 2017;323:53\u201365.","journal-title":"Toxicol Appl Pharmacol"},{"key":"1233_CR48","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13195-015-0167-5","volume":"8","author":"AG Elkahloun","year":"2016","unstructured":"Elkahloun AG, Hafko R, Saavedra JM. An integrative genome-wide transcriptome reveals that candesartan is neuroprotective and a candidate therapeutic for Alzheimer\u2019s disease. Alzheimers Res Ther. 2016;8:5.","journal-title":"Alzheimers Res Ther"},{"key":"1233_CR49","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12916-014-0160-z","volume":"12","author":"R Valenti","year":"2014","unstructured":"Valenti R, Pantoni L, Markus HS. Treatment of vascular risk factors in patients with a diagnosis of Alzheimer\u2019s disease: a systematic review. BMC Med. 2014;12:160.","journal-title":"BMC Med"},{"key":"1233_CR50","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13195-015-0106-5","volume":"7","author":"JA Cannon","year":"2015","unstructured":"Cannon JA, McMurray JJ, Quinn TJ. \u201cHearts and minds\u201d: association, causation and implication of cognitive impairment in heart failure. Alzheimers Res Ther. 2015;7:22.","journal-title":"Alzheimers Res Ther"},{"key":"1233_CR51","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/S0140-6736(04)17142-0","volume":"364","author":"H Debiec","year":"2004","unstructured":"Debiec H, Nauta J, Coulet F, van der Burg M, Guigonis V, Schurmans T, de Heer E, Soubrier F, Janssen F, Ronco P. Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies. Lancet. 2004;364:1252\u20139.","journal-title":"Lancet"},{"key":"1233_CR52","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/ng.2802","volume":"45","author":"JC Lambert","year":"2013","unstructured":"Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, DeStafano AL, Bis JC, Beecham GW, Grenier-Boley B, Russo G, Thorton-Wells TA, Jones N, Smith AV, Chouraki V, Thomas C, Ikram MA, Zelenika D, Vardarajan BN, Kamatani Y, Amouyel P. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer\u2019s disease. Nat Genet. 2013;45:1452\u20138.","journal-title":"Nat Genet"},{"key":"1233_CR53","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.febslet.2013.12.038","volume":"588","author":"P Sorrentino","year":"2014","unstructured":"Sorrentino P, Iuliano A, Polverino A, Jacini F, Sorrentino G. The dark sides of amyloid in Alzheimer\u2019s disease pathogenesis. FEBS Lett. 2014;588:641\u201352.","journal-title":"FEBS Lett"},{"key":"1233_CR54","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1021\/acschemneuro.1c00432","volume":"12","author":"JP Leite","year":"2021","unstructured":"Leite JP, Lete MG, Fowler SB, Gimeno A, Rocha JF, Sousa SF, Webster CI, Jim\u00e9nez-Bar Bero JJ, Gales L. A\u03b231-35 decreases neprilysin-mediated Alzheimer\u2019s amyloid-\u03b2 peptide degradation. ACS Chem Neurosci. 2021;12:3708\u201318.","journal-title":"ACS Chem Neurosci"},{"key":"1233_CR55","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrneurol.2017.188","volume":"14","author":"MD Sweeney","year":"2018","unstructured":"Sweeney MD, Sagare AP, Zlokovic BV. Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol. 2018;14:133\u201350.","journal-title":"Nat Rev Neurol"},{"key":"1233_CR56","doi-asserted-by":"crossref","first-page":"174480691773699","DOI":"10.1177\/1744806917736993","volume":"13","author":"S Pitake","year":"2017","unstructured":"Pitake S, Debrecht J, Mishra SK. Brain natriuretic peptide (BNP) expressing sensory neurons are not involved in acute, inflammatory or neuropathic pain. Mol Pain. 2017;13:1744806917736993.","journal-title":"Mol Pain"},{"key":"1233_CR57","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.neuint.2012.04.013","volume":"61","author":"I Guevara-Lora","year":"2012","unstructured":"Guevara-Lora I. Kinin-mediated inflammation in neurodegenerative disorders. Neurochem Int. 2012;61:72\u20138.","journal-title":"Neurochem Int"},{"key":"1233_CR58","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/j.ajpath.2013.01.021","volume":"182","author":"GF Passos","year":"2013","unstructured":"Passos GF, Medeiros R, Cheng D, Vasilevko V, Laferla FM, Cribbs DH. The bradykinin B1 receptor regulates A\u03b2 deposition and neuroinflammation in Tg-SwDI mice. Am J Pathol. 2013;182:1740\u20139.","journal-title":"Am J Pathol"},{"key":"1233_CR59","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/1753-0407.13389","volume":"15","author":"FH AlAnazi","year":"2023","unstructured":"AlAnazi FH, Al-Kuraishy HM, Al-Gareeb AI, Alexiou A, Papadakis M, Ogaly HA, Alanazi YA, Saad HM, Batiha GE-S. Effects of neprilysin and neprilysin inhibitors on glucose homeostasis: controversial points and a promising arena. J Diabetes. 2023;15:397\u2013408.","journal-title":"J Diabetes"},{"key":"1233_CR60","doi-asserted-by":"crossref","first-page":"964","DOI":"10.2174\/1567205013666160401114039","volume":"13","author":"C Severini","year":"2016","unstructured":"Severini C, Petrella C, Calissano P. Substance P and alzheimer\u2019s disease: emerging novel roles. Curr Alzheimer Res. 2016;13:964\u201372.","journal-title":"Curr Alzheimer Res"},{"issue":"2","key":"1233_CR61","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3390\/biomedicines10020343","volume":"10","author":"XY Yeo","year":"2022","unstructured":"Yeo XY, Cunliffe G, Ho RC, Lee SS, Jung S. Potentials of neuropeptides as therapeutic agents for neurological diseases. Biomedicines. 2022;10(2):343.","journal-title":"Biomedicines."},{"key":"1233_CR62","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.2174\/0115680266293416240515075450","volume":"24","author":"M Abubakar","year":"2024","unstructured":"Abubakar M, Nama L, Ansari MA, Ansari MM, Bhardwaj S, Daksh R, Syamala KLV, Jamadade MS, Chhabra V, Kumar D, Kumar N. GLP-1\/GIP agonist as an intriguing and ultimate remedy for combating Alzheimer\u2019s disease through its supporting DPP4 inhibitors: a review. Curr Top Med Chem. 2024;24:1635\u201364.","journal-title":"Curr Top Med Chem"},{"key":"1233_CR63","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13643-024-02464-w","volume":"13","author":"C Cheurfa","year":"2024","unstructured":"Cheurfa C, Tsokani S, Kontouli K-M, Boutron I, Chaimani A. Synthesis methods used to combine observational studies and randomised trials in published meta-analyses. Syst Rev. 2024;13:70.","journal-title":"Syst Rev"},{"key":"1233_CR64","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/ejhf.222","volume":"17","author":"P Cermakova","year":"2015","unstructured":"Cermakova P, Lund LH, Fereshtehnejad S-M, Johnell K, Winblad B, Dahlstr\u00f6m U, Eriksdotter M, Religa D. Heart failure and dementia: survival in relation to types of heart failure and different dementia disorders. Eur J Heart Fail. 2015;17:612\u20139.","journal-title":"Eur J Heart Fail"},{"key":"1233_CR65","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jamaneurol.2023.4719","volume":"81","author":"WS Brum","year":"2024","unstructured":"Brum WS, Docherty KF, Ashton NJ, Zetterberg H, Hansson O, McMurray JJV, Blennow K. Effect of neprilysin inhibition on alzheimer disease plasma biomarkers: a secondary analysis of a randomized clinical trial. JAMA Neurol. 2024;81:197\u2013200.","journal-title":"JAMA Neurol"},{"issue":"4","key":"1233_CR66","doi-asserted-by":"crossref","DOI":"10.1111\/1755-5922.12272","volume":"35","author":"C Krittanawong","year":"2017","unstructured":"Krittanawong C, Kitai T. Pharmacogenomics of angiotensin receptor\/neprilysin inhibitor and its long-term side effects. Cardiovasc Ther. 2017;35(4): e12272.","journal-title":"Cardiovasc Ther"},{"key":"1233_CR67","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jalz.2019.04.001","volume":"15","author":"L Vermunt","year":"2019","unstructured":"Vermunt L, Sikkes SAM, van den Hout A, Handels R, Bos I, van der Flier WM, Kern S, Ousset P-J, Maruff P, Skoog I, Verhey FRJ, Freund-Levi Y, Tsolaki M, Wallin \u00c5K, Olde Rikkert M, Soininen H, Spiru L, Zetterberg H, Blennow K, Scheltens P, ICTUS\/DSA study groups. Duration of preclinical, prodromal, and dementia stages of Alzheimer\u2019s disease in relation to age, sex, and APOE genotype. Alzheimers Dement. 2019;15:888\u201398.","journal-title":"Alzheimers Dement"},{"key":"1233_CR68","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.cardfail.2017.04.007","volume":"23","author":"JA Cannon","year":"2017","unstructured":"Cannon JA, Moffitt P, Perez-Moreno AC, Walters MR, Broomfield NM, McMurray JJV, Quinn TJ. Cognitive impairment and heart failure: systematic review and meta-analysis. J Card Fail. 2017;23:464\u201375.","journal-title":"J Card Fail"},{"key":"1233_CR69","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.hjc.2022.07.005","volume":"67","author":"NLX Yap","year":"2022","unstructured":"Yap NLX, Kor Q, Teo YN, Teo YH, Syn NL, Evangelista LKM, Tan BY, Lin W, Yeo LL, Kong WK, Chong YF, Wong RC, Poh KK, Yeo T-C, Sharma VK, Chai P, Chan MY, Goh FQ, Sia C-H. Prevalence and incidence of cognitive impairment and dementia in heart failure\u2014a systematic review, meta-analysis and meta-regression. Hellenic J Cardiol. 2022;67:48\u201358.","journal-title":"Hellenic J Cardiol"},{"key":"1233_CR70","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.cardfail.2021.12.014","volume":"28","author":"S Vishwanath","year":"2022","unstructured":"Vishwanath S, Qaderi V, Steves CJ, Reid CM, Hopper I, Ryan J. Cognitive decline and risk of dementia in individuals with heart failure: a systematic review and meta-analysis. J Card Fail. 2022;28:1337\u201348.","journal-title":"J Card Fail"},{"key":"1233_CR71","doi-asserted-by":"crossref","unstructured":"Jahangiri S, Kazakov E, Amancherla S & Kalogeropoulos AP. Impact of heart failure medications on cognitive function: a systematic review. Eur J Clin Invest. 2025;e70008.","DOI":"10.1111\/eci.70008"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-025-01233-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-025-01233-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-025-01233-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T03:51:15Z","timestamp":1759204275000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-025-01233-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,29]]},"references-count":71,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1233"],"URL":"https:\/\/doi.org\/10.1007\/s40266-025-01233-1","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,29]]},"assertion":[{"value":"3 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"Mohamed Mohsen Helal, Nereen A. Almosilhy, Nada G. Hamam, Mohamed Ahmed Adel Abdelbaset, Ali Nagy Shelbaya, Halima Abdirashid Y. Musse, and Aishwarya Prasad declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"No funding was received to assist with the preparation of this manuscript.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"M.M.H. conceived the study idea, developed the overall design and direction, conducted the analysis, contributed to writing, and provided supervision. N.A.A. supervised the screening process and contributed to writing. N.G.H. oversaw the screening, data extraction quality assessment processes, and contributed to writing. M.A. and A.N.S. contributed to screening, data extraction, quality assessment, and writing. H.M. and A.P. contributed to writing.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}